FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1949589692> ?p ?o ?g. }

• W1949589692 endingPage "1730" @default.
• W1949589692 startingPage "1718" @default.
• W1949589692 abstract "Breast cancer is one of the most common and feared cancers faced by women. The prognosis of patients with advanced or recurrent breast cancer remains poor despite refinements in multimodality therapies involving chemotherapeutic and hormonal agents. Multimodal therapy with more specific and effective strategy is urgently needed. The oncolytic herpes simplex virus (HSV) has potential to become a new effective treatment option because of its broad host range and tumor selective viral distribution. Bevacizumab is a monoclonal antibody against VEGFA, which inhibits angiogenesis and therefore tumor growth. Our approach to enhance the antitumor effect of the oncolytic HSV is to combine oncolytic HSV HF10 and bevacizumab in the treatment of breast cancer. Our results showed that bevacizumab enhanced viral distribution as well as tumor hypoxia and expanded the population of apoptotic cells and therefore induced a synergistic antitumor effect. HF10 is expected to be a promising agent in combination with bevacizumab in the anticancer treatment." @default.
• W1949589692 created "2016-06-24" @default.
• W1949589692 creator A5018146056 @default.
• W1949589692 creator A5020004419 @default.
• W1949589692 creator A5022391772 @default.
• W1949589692 creator A5024745153 @default.
• W1949589692 creator A5024920182 @default.
• W1949589692 creator A5026524817 @default.
• W1949589692 creator A5033158958 @default.
• W1949589692 creator A5034042835 @default.
• W1949589692 creator A5034871080 @default.
• W1949589692 creator A5034886325 @default.
• W1949589692 creator A5039896704 @default.
• W1949589692 creator A5047606517 @default.
• W1949589692 creator A5053926235 @default.
• W1949589692 creator A5055435217 @default.
• W1949589692 creator A5056199894 @default.
• W1949589692 creator A5064537793 @default.
• W1949589692 creator A5067510670 @default.
• W1949589692 creator A5068357715 @default.
• W1949589692 creator A5069900499 @default.
• W1949589692 creator A5071073232 @default.
• W1949589692 creator A5080220066 @default.
• W1949589692 creator A5081272654 @default.
• W1949589692 creator A5088026760 @default.
• W1949589692 date "2014-09-27" @default.
• W1949589692 modified "2023-10-01" @default.
• W1949589692 title "Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft" @default.
• W1949589692 cites W1503667331 @default.
• W1949589692 cites W1564446710 @default.
• W1949589692 cites W1929814745 @default.
• W1949589692 cites W1961949089 @default.
• W1949589692 cites W1980973208 @default.
• W1949589692 cites W1991893508 @default.
• W1949589692 cites W1999009503 @default.
• W1949589692 cites W2011199583 @default.
• W1949589692 cites W2025822798 @default.
• W1949589692 cites W2025822934 @default.
• W1949589692 cites W2026344055 @default.
• W1949589692 cites W2027881042 @default.
• W1949589692 cites W2028156849 @default.
• W1949589692 cites W2030479138 @default.
• W1949589692 cites W2031714805 @default.
• W1949589692 cites W2038465786 @default.
• W1949589692 cites W2045415534 @default.
• W1949589692 cites W2047014766 @default.
• W1949589692 cites W2050921603 @default.
• W1949589692 cites W2053062203 @default.
• W1949589692 cites W2057672138 @default.
• W1949589692 cites W2077302818 @default.
• W1949589692 cites W2079461024 @default.
• W1949589692 cites W2086011860 @default.
• W1949589692 cites W2090732350 @default.
• W1949589692 cites W2094320870 @default.
• W1949589692 cites W2104605014 @default.
• W1949589692 cites W2104709544 @default.
• W1949589692 cites W2106253728 @default.
• W1949589692 cites W2107053205 @default.
• W1949589692 cites W2117329021 @default.
• W1949589692 cites W2118728917 @default.
• W1949589692 cites W2125733229 @default.
• W1949589692 cites W2128450583 @default.
• W1949589692 cites W2135836641 @default.
• W1949589692 cites W2154131697 @default.
• W1949589692 cites W2154420394 @default.
• W1949589692 cites W2156950231 @default.
• W1949589692 cites W2157657933 @default.
• W1949589692 cites W2160335399 @default.
• W1949589692 cites W2169961966 @default.
• W1949589692 cites W2170625748 @default.
• W1949589692 cites W2325605933 @default.
• W1949589692 cites W2329898359 @default.
• W1949589692 doi "https://doi.org/10.1002/ijc.29163" @default.
• W1949589692 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25156870" @default.
• W1949589692 hasPublicationYear "2014" @default.
• W1949589692 type Work @default.
• W1949589692 sameAs 1949589692 @default.
• W1949589692 citedByCount "47" @default.
• W1949589692 countsByYear W19495896922015 @default.
• W1949589692 countsByYear W19495896922016 @default.
• W1949589692 countsByYear W19495896922017 @default.
• W1949589692 countsByYear W19495896922018 @default.
• W1949589692 countsByYear W19495896922019 @default.
• W1949589692 countsByYear W19495896922020 @default.
• W1949589692 countsByYear W19495896922021 @default.
• W1949589692 countsByYear W19495896922022 @default.
• W1949589692 countsByYear W19495896922023 @default.
• W1949589692 crossrefType "journal-article" @default.
• W1949589692 hasAuthorship W1949589692A5018146056 @default.
• W1949589692 hasAuthorship W1949589692A5020004419 @default.
• W1949589692 hasAuthorship W1949589692A5022391772 @default.
• W1949589692 hasAuthorship W1949589692A5024745153 @default.
• W1949589692 hasAuthorship W1949589692A5024920182 @default.
• W1949589692 hasAuthorship W1949589692A5026524817 @default.
• W1949589692 hasAuthorship W1949589692A5033158958 @default.
• W1949589692 hasAuthorship W1949589692A5034042835 @default.
• W1949589692 hasAuthorship W1949589692A5034871080 @default.
• W1949589692 hasAuthorship W1949589692A5034886325 @default.

• next